Literature DB >> 29126031

NLRP3 inflammasome pathways in atherosclerosis.

Marta Baldrighi1, Ziad Mallat2, Xuan Li3.   

Abstract

Atherosclerosis is the major cause of death and disability. Atherosclerotic plaques are characterized by a chronic sterile inflammation in the large blood vessels, where lipid-derived and damage-associated molecular patterns play important roles in inciting immune responses. Following the initial demonstration that NLR family Pyrin domain containing 3 (NLRP3) was important for atherogenesis, a substantial number of studies have emerged addressing the basic mechanisms of inflammasome activation and their relevance to atherosclerosis. In this review, we introduce the basic cellular and molecular mechanisms of NLRP3 inflammasome activation, and discuss the current findings and therapeutic strategies that target NLRP3 inflammasome activation during the development and progression of atherosclerosis. Crown
Copyright © 2017. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ASC; Atherosclerosis; Caspase-1; IL-1β; NLRP3 inflammasome

Mesh:

Substances:

Year:  2017        PMID: 29126031     DOI: 10.1016/j.atherosclerosis.2017.10.027

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  54 in total

1.  Embryonic stem cell-derived exosomes inhibit doxorubicin-induced TLR4-NLRP3-mediated cell death-pyroptosis.

Authors:  Zahra Tavakoli Dargani; Dinender K Singla
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-06-07       Impact factor: 4.733

2.  Imbalance in thioredoxin system activates NLRP3 inflammasome pathway in epicardial adipose tissue of patients with coronary artery disease.

Authors:  Hossein Shateri; Babak Manafi; Heidar Tayebinia; Jamshid Karimi; Iraj Khodadadi
Journal:  Mol Biol Rep       Date:  2021-02-10       Impact factor: 2.316

3.  Fibroblast growth factor 21 attenuates inflammation and oxidative stress in atherosclerotic rat via enhancing the Nrf1-ARE signaling pathway.

Authors:  Haizhen Jia; Jing Cheng; Qi Zhou; Jun Peng; Yunhong Pan; Hongyan Han
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

Review 4.  Novel Antiatherosclerotic Therapies.

Authors:  Peter Libby; Brendan M Everett
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-04       Impact factor: 8.311

Review 5.  Cytokine Circuits in Cardiovascular Disease.

Authors:  Jesse W Williams; Li-Hao Huang; Gwendalyn J Randolph
Journal:  Immunity       Date:  2019-04-16       Impact factor: 31.745

6.  P2X Antagonists Inhibit HIV-1 Productive Infection and Inflammatory Cytokines Interleukin-10 (IL-10) and IL-1β in a Human Tonsil Explant Model.

Authors:  Alexandra Y Soare; Natasha D Durham; Ramya Gopal; Benjamin Tweel; Kevin W Hoffman; Julia A Brown; Megan O'Brien; Nina Bhardwaj; Jean K Lim; Benjamin K Chen; Talia H Swartz
Journal:  J Virol       Date:  2018-12-10       Impact factor: 5.103

Review 7.  Immunological mechanisms underlying sterile inflammation in the pathogenesis of atherosclerosis: potential sites for intervention.

Authors:  Roland Truong; Finosh G Thankam; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2020-12-21       Impact factor: 4.473

8.  YAP promotes the activation of NLRP3 inflammasome via blocking K27-linked polyubiquitination of NLRP3.

Authors:  Dan Wang; Yening Zhang; Xueming Xu; Jianfeng Wu; Yue Peng; Jing Li; Ruiheng Luo; Lingmin Huang; Liping Liu; Songlin Yu; Ningjie Zhang; Ben Lu; Kai Zhao
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

9.  Ox-LDL Causes Endothelial Cell Injury Through ASK1/NLRP3-Mediated Inflammasome Activation via Endoplasmic Reticulum Stress.

Authors:  Liwei Hang; Yan Peng; Rui Xiang; Xiangdong Li; Zhiliang Li
Journal:  Drug Des Devel Ther       Date:  2020-02-24       Impact factor: 4.162

10.  TAS-116, a Well-Tolerated Hsp90 Inhibitor, Prevents the Activation of the NLRP3 Inflammasome in Human Retinal Pigment Epithelial Cells.

Authors:  Sofia Ranta-Aho; Niina Piippo; Eveliina Korhonen; Kai Kaarniranta; Maria Hytti; Anu Kauppinen
Journal:  Int J Mol Sci       Date:  2021-05-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.